Open an Account
search icon
2
NOTIFICATIONS
Best Algo trading app in India
Bigul

Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

 Pursuant to the recommendation of Nomination and Remuneration Committee, the Board of Directors of the Company in their meeting held today has granted 25,000 stock options to eligible employees under the Strides ESOP Plan 2016 at Rs. 599/- per option (exercise price). The shares covered by such options are 25,000 equity shares. The vesting period of these options is in a phased manner over a period of 3 years. The options are exercisable within a period of 12 months (exercisable in not more than two tranches) from the date of vesting.
27-05-2021
Bigul

Strides Pharma Science Ltd - 532531 - Corporate Action-Board approves Dividend

 The Board of Directors at their meeting held today i.e., on May 27, 2021, have recommended final dividend of Rs. 2.50 /- per equity share of Rs. 10/- each for the financial year ended March 31, 2021. The dividend will be paid within 30 days from the date of shareholder's approval at the ensuing Annual General Meeting of the Company. This is for your information and record.
27-05-2021
Bigul

Strides Pharma Science Ltd - 532531 - Outcome Of Board Meeting - Audited Financial Results (Standalone & Consolidated) For The Quarter And Year Ended March 31, 2021

 The Board of Directors at their meeting held today i.e., on May 27, 2021, has inter-alia, approved the Audited Financial Statements (Standalone and Consolidated) of the Company for the quarter and year ended March 31, 2021. In this regard, please find enclosed the following: 1. A copy of the Audited Financial Statements (Standalone and Consolidated) for the quarter and year ended March 31, 2021 along with Auditors' Report for the said period; 2. Declaration on Unmodified Opinion in the Auditors' Report for Financial Year ended March 31, 2021; and 3. Press Release tilted 'Strides reports strong FY21 performance with 29% revenue and 67% EBITDA growth'. The Board Meeting commenced at 11:45 hrs and concluded at 13:15 hrs. This is for your information and record.
27-05-2021
Bigul

Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 TLC and Strides partner to launch Liposomal Amphotericin B in India
27-05-2021
Bigul

Annual report for Strides Pharma Science Ltd. for FY-2021
27-05-2021
Bigul

Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 Earnings Call for discussion of audited financial results for the quarter and year ended March 31, 2021.
26-05-2021
Bigul

Strides Pharma Science Ltd - 532531 - Disclosure Under Regulation 30 Of SEBI Listing Regulations

 Update on completion of Series C funding in Stelis
25-05-2021

Strides Ventures announces new fund, targets corpus of up to Rs 1,875 crore

 The firm will continue investing in early to late-stage startups with ticket size from the new fund expected to go up to Rs 70 crore, Strides Ventures said in a statement.
25-05-2021
Bigul

Strides Pharma Science Ltd - 532531 - Board to consider FY21 results & Dividend on May 27, 2021

 Strides Pharma Science Ltd has informed BSE that a meeting of Board of Directors of the Company is scheduled to be heldon May 27, 2021, to consider and approve the audited financial results (standalone and consolidated) of the Company for the quarter and year ended March 31, 2021 and recommendation of dividend, if any, amongst other matters.Further, as per the provisions of the Company's Code of Conduct for Prohibition of Insider Trading, trading window for designated persons of the Company is closed from April 01, 2021 upto May 29, 2021 (both days inclusive).
20-05-2021
Bigul

Strides Pharma Science Ltd - 532531 - Board Meeting Intimation for Announcement Of Board Meeting Under Regulation 29 Of SEBI Listing Regulations

 Strides Pharma Science Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/05/2021 ,inter alia, to consider and approve This is to inform you that a meeting of Board of Directors of the Company is scheduled to be held on Thursday, May 27, 2021 to consider and approve the audited financial results (standalone and consolidated) of the Company for the quarter and year ended March 31, 2021 and recommendation of dividend, if any, amongst other matters. Further, as per the provisions of the Company's Code of Conduct for Prohibition of Insider Trading, trading window for designated persons of the Company is closed from Thursday, April 1, 2021 upto Saturday, May 29, 2021 (both days inclusive). This is for your kind information and record purposes.
20-05-2021
Next Page
Close

Let's Open Free Demat Account